Drugs

, Volume 77, Issue 18, pp 2049–2056 | Cite as

Aripiprazole Lauroxil: A Review in Schizophrenia

Adis Drug Evaluation

Abstract

Aripiprazole lauroxil long-acting injectable (LAI) [Aristada®] is an intramuscularly administered, extended-release prodrug of aripiprazole, an established atypical antipsychotic agent that, in terms of its relative position within the class, is at the low end of the risk spectrum for metabolic side effects. In the USA, aripiprazole lauroxil LAI is indicated for the treatment of schizophrenia; approved doses of the drug can be injected once-monthly (q4w), every 6 weeks (q6w) or every 2 months (q8w). The efficacy of the 441 and 882 mg q4w dosages in the treatment of acute exacerbations of schizophrenia and as long-term maintenance therapy in stable schizophrenia has been directly demonstrated in a phase III clinical trial and extension, while the efficacy of the 662 mg q4w, 882 mg q6w and 1064 mg q8w dosing regimens has been established on the basis of pharmacokinetic bridging studies. Aripiprazole lauroxil LAI therapy was generally well tolerated, with an adverse event profile consistent with that of oral aripiprazole (with the exception of injection-site reactions), including a low propensity to cause metabolic disturbances. Thus, aripiprazole lauroxil LAI extends the treatment regimen options for patients with schizophrenia; as with other LAI formulations of antipsychotic agents, it can be particularly recommended for patients with recurrent relapses related to nonadherence to oral preparations and for those who prefer this mode of administration. Moreover, unlike aripiprazole monohydrate LAI, the only other commercially available long-acting formulation of aripiprazole, aripiprazole lauroxil LAI offers more than one dosing interval option, which may be a potential advantage in terms of tailoring therapy to the needs of individual patients.

Notes

Acknowledgements

During the peer review process, the manufacturer of aripiprazole lauroxil LAI was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

James Frampton is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/8B4CF0607EB49AE7.

References

  1. 1.
    Patel KR, Cherian J, Gohil K, et al. Schizophrenia: overview and treatment options. PT. 2014;39(9):638–45.Google Scholar
  2. 2.
    Kreyenbuhl J, Buchanan RW, Dickerson FB, et al. The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94–103.CrossRefPubMedGoogle Scholar
  3. 3.
    Miyamoto S, Fleischhacker WW. The use of long-acting injectable antipsychotics in schizophrenia. Curr Treat Options Psychiatry. 2017;4:117–26.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bak M, Fransen A, Janssen J, et al. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014;9(4):e94112.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Lehman AF, Lieberman JA, Dixon LB, et al. American Psychiatric Association Practice Guidelines; Work Group on Schizophrenia. Practice guideline for the treatment of patients with schizophrenia, 2nd edn. Am J Psychiatry. 2004;161(Suppl 2):1–56.Google Scholar
  6. 6.
    Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1–93.PubMedGoogle Scholar
  7. 7.
    Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43–62.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Higashi K, Medic G, Littlewood KJ, et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200–18.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Brissos S, Veguilla MR, Taylor D, et al. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4(5):198–219.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(Suppl 3):1–24.CrossRefPubMedGoogle Scholar
  11. 11.
    Croxtall JD. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS Drugs. 2012;26(2):155–83.CrossRefPubMedGoogle Scholar
  12. 12.
    Aggarwal A, Gopalakrishna G, Lauriello J. Aripiprazole lauroxil long-acting injectable: the latest addition to second-generation long-acting agents. Clin Schizophr Relat Psychoses. 2016;10(1):58–63.CrossRefPubMedGoogle Scholar
  13. 13.
    Shirley M, Perry CM. Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia. Drugs. 2014;74:1097–110.CrossRefPubMedGoogle Scholar
  14. 14.
    Citrome L. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Expert Rev Clin Pharmacol. 2016;9(2):169–86.CrossRefPubMedGoogle Scholar
  15. 15.
    US FDA. ABILIFY MAINTENA® (aripiprazole) for extended-release injectable suspension, for intramuscular use: US prescribing information. 2016. https://www.accessdata.fda.gov. Accessed 4 Jul 2017.
  16. 16.
    Center for Drug Evaluation and Research. Application number: 207533Orig1s000. Summary review. https://www.accessdata.fda.gov. Accessed 30 Aug 2017.
  17. 17.
    Rohde M, Niels M, Hakansson AE, et al. Biological conversion of aripiprazole lauroxil—an N-acyloxymethyl aripiprazole prodrug. Results Pharma Sci. 2014;4:19–25.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Alkermes Inc. Aristada® (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular use: US prescribing information. 2017. https://www.aristadahcp.com. Accessed 4 Jul 2017.
  19. 19.
    Hard ML, Mills RJ, Sadler BM, et al. Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia. J Clin Psychopharmacol. 2017;37(3):289–95.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Hard ML, Mills RJ, Sadler BM, et al. Pharmacokinetic profile of a 2-month dose regimen of aripiprazole lauroxil: a phase I study and a population pharmacokinetic model. CNS Drugs. 2017;31(7):617–24.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Turncliff R, Hard M, Du Y, et al. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. Schizophr Res. 2014;159(2–3):404–10.CrossRefPubMedGoogle Scholar
  22. 22.
    Meltzer HY, Risinger R, Nasrallah HA, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry. 2015;76(8):1085–90.CrossRefPubMedGoogle Scholar
  23. 23.
    Center for Drug Evaluation and Research. Application number: 207533Orig1s000. Clinical Pharmacology and Biopharmaceutics Review(s). https://www.accessdata.fda.gov. Accessed 30 Aug 2017.
  24. 24.
    Targum SD, Risinger R, Du Y, et al. Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia. Schizophr Res. 2017;179:64–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Potkin SG, Risinger R, Du Y, et al. Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation. Schizophr Res. 2017. https://doi.org/10.1016/j.schres.2017.03.003.Google Scholar
  26. 26.
    Stanford A, Risinger R, Claxton A, et al. Social and functional outcomes: results: from a 12-week phase 3 study of 2 doses aripiprazole lauroxil vs placebo: a post hoc analysis [abstract]. Schizophr Bull. 2017;43:S218.CrossRefGoogle Scholar
  27. 27.
    Citrome L, Du Y, Risinger R, et al. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. Int Clin Psychopharmacol. 2016;31(2):69–75.CrossRefPubMedGoogle Scholar
  28. 28.
    Citrome L, Risinger R, Cutler AJ, et al. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study. CNS Spectr. 2017;1–7.Google Scholar
  29. 29.
    US National Institutes of Health. ClinicalTrials.gov identifier NCT01626456. 2016. https://clinicaltrials.gov. Accessed 7 Aug 2017.
  30. 30.
    McEvoy JP, Risinger R, Mykhnyak S, et al. Durability of therapeutic response with long-term aripiprazole lauroxil treatment following successful resolution of an acute episode of schizophrenia. J Clin Psychiatry. 2017;78(8):1103–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Risinger R, Stanford A, Du Y, et al. Long-term safety and durability of effect of aripiprazole lauroxil in a 1-year schizophrenia extension study [abstract no. T59 plus poster P51]. npj Schizophrenia (2016) 2, Article number: 16007. https://doi.org/10.1038/npjschz.2016.7.
  32. 32.
    Stanford A, Risinger R, Du Y, et al. Stability in a 52-week schizophrenia extension study of treatment with long-acting injectable aripiprazole lauroxil [abstract no. M61 plus poster no. P49]. npj Schizophrenia (2016) 2, Article number: 16008. https://doi.org/10.1038/npjschz.2016.8.
  33. 33.
    Weiden PJ, Risinger R, Stanford AD, et al. Switching stable schizophrenia patients from oral antipsychotics to monthly aripiprazole lauroxil: a post hoc analysis of a long-term outpatient study [poster no. #134]. In: US Psychiatric and Mental Health Congress; 2016.Google Scholar
  34. 34.
    Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Potkin SG, Du Y, Claxton A, et al. Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: a 6-month, prospective, open-label study [poster no. 259]. In: 30th US Psychiatric and Mental Health Congress; 2017.Google Scholar
  36. 36.
    Nasrallah HA, Newcomer JW, Risinger R, et al. Effect of aripiprazole lauroxil on metabolic and endocrine profiles and related safety considerations among patients with acute schizophrenia. J Clin Psychiatry. 2016;77(11):1519–25.CrossRefPubMedGoogle Scholar
  37. 37.
    Nasrallah HA, Aquila R, Stanford AD, et al. Metabolic and endocrine profiles during 1-year treatment of outpatients with schizophrenia with aripiprazole lauroxil [poster no. P5-009]. In: Poster Proceedings. American Psychiatric Association Annual Meeting; 2017.Google Scholar
  38. 38.
    Risinger R, Hard M, Weiden PJ. A phase 1 study comparing pharmacokinetic and safety profiles of three different dose intervals of aripiprazole lauroxil [poster no. P5-025]. In: Poster Proceedings. American Psychiatric Association Annual Meeting; 2017.Google Scholar
  39. 39.
    Alkermes plc. Alkermes to initiate new clinical study evaluating ARISTADA® and INVEGA SUSTENNA® for the treatment of schizophrenia [media release]. 26 Oct 2017. http://www.alkermes.com.
  40. 40.
    Cameron C, Zummo J, Desai DN, et al. Aripiprazole lauroxil compared with paliperidone palmitate in patients with schizophrenia: an indirect treatment comparison. Value Health. 2017. https://doi.org/10.1016/j.jval.2017.03.010.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2017

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations